Purpose: The effectiveness of every-three-week administration of darbepoetin alfa in women with chemotherapy-associated anemia was evaluated. Methods: Women receiving chemotherapy for gynecological ...

Darbepoetin can be administered either intravenously (i.v.) or subcutaneously (s.c.). However, no information is available regarding pharmacokinetics and pharmacodynamics following its i.v.

THOUSAND OAKS, Calif., (March 27, 2006) – Amgen (NASDAQ: AMGN), the world's largest biotechnology company, today announced the U.S. Food and Drug Administration (FDA) has approved every-three-week ...

BARCELONA, Spain -- Sept. 26, 2007--Amgen today announced data from a Phase 2, randomized, multicenter, open-label study that suggest extended dosing of Aranesp(R) (darbepoetin alfa) paired with ...

Darbepoetin is longer acting and more potent than recombinant erythropoietin (rEpo). In certain situations, preterm neonates might benefit from rEpo, and for such patients darbepoetin would require ...

ORLANDO, Fla., (May 15, 2005) – Amgen Inc., (NASDAQ: AMGN) the world's largest biotechnology company, today announced that new interim data from a single-arm, open label study of 1,225 cancer patients ...

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen, Inc. (NASDAQ: AMGN - News) today announced that it had received interim results from the independent investigator-sponsored “PREPARE†study, an ...

LOS ANGELES, April 16 (Reuters) - Amgen Inc. said on Monday that 48.5 percent of cancer patients not undergoing chemotherapy or radiation who received its anemia drug Aranesp in a clinical trial died ...

STOCKHOLM—Whether darbepoetin alfa (DA) is administered in the middle or at the end of a hemodialysis session has no significant effect on hemoglobin levels, according to a French study. Some in vitro ...

Patient characteristics are summarized in Table 1 . A total of 14 patients received at least one dose of darbepoetin alfa, and the 12 who received more than one dose were assessable. Eleven patients ...